Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial
Experimental and clinical evidence has recently shown that pluripotent stem cells can be mobilized by granulocyte colony-stimulating factor (G-CSF) and may enhance myocardial regeneration early after primary percutaneous coronary intervention (PCI) management of acute myocardial infarction. Sustaine...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2005-08, Vol.112 (9), p.I73-I80 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | I80 |
|---|---|
| container_issue | 9 |
| container_start_page | I73 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 112 |
| creator | INCE, Hüseyin PETZSCH, Michael KLEINE, Hans Dieter ECKARD, Heike REHDERS, Tim BURSKA, Detlev KISCHE, Stephan FREUND, Mathias NIENABER, Christoph A |
| description | Experimental and clinical evidence has recently shown that pluripotent stem cells can be mobilized by granulocyte colony-stimulating factor (G-CSF) and may enhance myocardial regeneration early after primary percutaneous coronary intervention (PCI) management of acute myocardial infarction. Sustained or long-term effects of mobilized CD34-positive mononuclear stem cells, however, are unknown.
Thirty consecutive patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab were selected for the study 85+/-30 minutes after PCI; 15 patients were randomly assigned to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care including aspirin, clopidogrel, an angiotensin-converting enzyme inhibitor, beta-blocking agents, and statins. In patients with comparable demographics and clinical and infarct-related characteristics, G-CSF stimulation led to sustained mobilization of CD34 positive mononuclear cells (MNC(CD34+)), with a 20-fold increase (from 3+/-2 at baseline to 66+/-54 MNC(CD34+)/microL on day 6; P |
| doi_str_mv | 10.1161/CIRCULATIONAHA.104.524827 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68570523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68570523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c252t-a8af444e671ac3a02f6b06157dabbeef42a90ac9ad1e83484355c68f11560a553</originalsourceid><addsrcrecordid>eNqNUk1v1DAQDQhEl8JfQOYAgkMWO9_htlp1aaSlRWV7jibOuDVy7GI7i8Kvx9ldqeKCuNiemTfz3ownit4yumSsYJ_Wzc36drvaNddXq8vVktFsmSdZlZRPowULrzjL0_pZtKCU1nGZJslZ9NK5H8Es0jJ_EZ2FInldFfXiSfHN4h61l0YTI4hC4clsW8lHBZZYHEyPSuo78kv6e3JnQY_K8Mkj4UYZPcXOyyFg_YwRwL2xBITHcPIxoIbJcLC9BEWkFmD5zPWZbKQOHhZPeGBxo_JuVuDvkQhrtI-l9hjoPPYhvgd3ECR_w0Er6J44jwPhqBRRskN7DEhNcG_UflbzDwGkm_6zlw-b5ub7bttcXcSrr81HEkYD6lX0XIBy-Pp0n0e3m4vd-jLeXn9p1qttzJM88TFUILIsw6JkwFOgiSg6GmZf9tB1iCJLoKbAa-gZVmlWZWme86ISjOUFhTxPz6P3x7oP1vwc0fl2kG5uGTSa0bVFlZc0T9IArI9Abo1zFkX7YOUAdmoZbeelaf9emuDO2uPShNw3J5KxG7B_zDxtSQC8OwHCL4ASYW5cukdcyWpa11n6B9OK1ks</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68570523</pqid></control><display><type>article</type><title>Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>INCE, Hüseyin ; PETZSCH, Michael ; KLEINE, Hans Dieter ; ECKARD, Heike ; REHDERS, Tim ; BURSKA, Detlev ; KISCHE, Stephan ; FREUND, Mathias ; NIENABER, Christoph A</creator><creatorcontrib>INCE, Hüseyin ; PETZSCH, Michael ; KLEINE, Hans Dieter ; ECKARD, Heike ; REHDERS, Tim ; BURSKA, Detlev ; KISCHE, Stephan ; FREUND, Mathias ; NIENABER, Christoph A</creatorcontrib><description><![CDATA[Experimental and clinical evidence has recently shown that pluripotent stem cells can be mobilized by granulocyte colony-stimulating factor (G-CSF) and may enhance myocardial regeneration early after primary percutaneous coronary intervention (PCI) management of acute myocardial infarction. Sustained or long-term effects of mobilized CD34-positive mononuclear stem cells, however, are unknown.
Thirty consecutive patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab were selected for the study 85+/-30 minutes after PCI; 15 patients were randomly assigned to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care including aspirin, clopidogrel, an angiotensin-converting enzyme inhibitor, beta-blocking agents, and statins. In patients with comparable demographics and clinical and infarct-related characteristics, G-CSF stimulation led to sustained mobilization of CD34 positive mononuclear cells (MNC(CD34+)), with a 20-fold increase (from 3+/-2 at baseline to 66+/-54 MNC(CD34+)/microL on day 6; P<0.001); there was no evidence of leukocytoclastic effects, accelerated restenosis rate, or any late adverse events. Within 4 months, G-CSF-induced MNC(CD34+) mobilization led to enhanced resting wall thickening in the infarct zone of 1.16+/-0.29 mm (P<0.05 versus control), which was sustained at 1.20+/-0.28 after 12 months (P<0.001 versus control). Similarly, left ventricular ejection fraction improved from 48+/-4% at baseline to 54+/-8% at 4 months (P<0.005 versus control) and 56+/-9% at 12 months (P<0.003 versus control and paralleled by sustained improvement of wall-motion score index from 1.70+/-0.22 to 1.42+/-0.26 and 1.33+/-0.21 at 4 and 12 months, respectively), after G-CSF (P<0.05 versus baseline and P<0.03 versus controls). Accordingly, left ventricular end-diastolic diameter showed no remodeling and stable left ventricular dimensions after G-CSF stimulation, whereas left ventricular end-diastolic diameter in controls revealed enlargement from 55+/-4 mm at baseline to 58+/-4 mm (P<0.05 versus baseline) at 12 months after infarction and no improvement in diastolic function.
Mobilization of MNC(CD34+) by G-CSF after primary PCI may offer a pragmatic strategy for improvement in ventricular function and prevention of left ventricular remodeling 1 year after acute myocardial infarction.]]></description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.104.524827</identifier><identifier>PMID: 16159869</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Angioplasty, Balloon, Coronary ; Antibodies, Monoclonal - therapeutic use ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Cell Count ; Blood vessels and receptors ; Cardiology. Vascular system ; Cardiovascular Agents - therapeutic use ; Combined Modality Therapy ; Coronary Angiography ; Coronary heart disease ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Heart ; Hematopoietic Stem Cell Mobilization ; Hematopoietic Stem Cells - drug effects ; Humans ; Immunoglobulin Fab Fragments - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - complications ; Myocardial Infarction - drug therapy ; Myocardial Infarction - therapy ; Postoperative Care ; Prospective Studies ; Stents ; Treatment Outcome ; Ventricular Function, Left ; Ventricular Remodeling - drug effects ; Vertebrates: cardiovascular system</subject><ispartof>Circulation (New York, N.Y.), 2005-08, Vol.112 (9), p.I73-I80</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c252t-a8af444e671ac3a02f6b06157dabbeef42a90ac9ad1e83484355c68f11560a553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17190994$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16159869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>INCE, Hüseyin</creatorcontrib><creatorcontrib>PETZSCH, Michael</creatorcontrib><creatorcontrib>KLEINE, Hans Dieter</creatorcontrib><creatorcontrib>ECKARD, Heike</creatorcontrib><creatorcontrib>REHDERS, Tim</creatorcontrib><creatorcontrib>BURSKA, Detlev</creatorcontrib><creatorcontrib>KISCHE, Stephan</creatorcontrib><creatorcontrib>FREUND, Mathias</creatorcontrib><creatorcontrib>NIENABER, Christoph A</creatorcontrib><title>Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description><![CDATA[Experimental and clinical evidence has recently shown that pluripotent stem cells can be mobilized by granulocyte colony-stimulating factor (G-CSF) and may enhance myocardial regeneration early after primary percutaneous coronary intervention (PCI) management of acute myocardial infarction. Sustained or long-term effects of mobilized CD34-positive mononuclear stem cells, however, are unknown.
Thirty consecutive patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab were selected for the study 85+/-30 minutes after PCI; 15 patients were randomly assigned to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care including aspirin, clopidogrel, an angiotensin-converting enzyme inhibitor, beta-blocking agents, and statins. In patients with comparable demographics and clinical and infarct-related characteristics, G-CSF stimulation led to sustained mobilization of CD34 positive mononuclear cells (MNC(CD34+)), with a 20-fold increase (from 3+/-2 at baseline to 66+/-54 MNC(CD34+)/microL on day 6; P<0.001); there was no evidence of leukocytoclastic effects, accelerated restenosis rate, or any late adverse events. Within 4 months, G-CSF-induced MNC(CD34+) mobilization led to enhanced resting wall thickening in the infarct zone of 1.16+/-0.29 mm (P<0.05 versus control), which was sustained at 1.20+/-0.28 after 12 months (P<0.001 versus control). Similarly, left ventricular ejection fraction improved from 48+/-4% at baseline to 54+/-8% at 4 months (P<0.005 versus control) and 56+/-9% at 12 months (P<0.003 versus control and paralleled by sustained improvement of wall-motion score index from 1.70+/-0.22 to 1.42+/-0.26 and 1.33+/-0.21 at 4 and 12 months, respectively), after G-CSF (P<0.05 versus baseline and P<0.03 versus controls). Accordingly, left ventricular end-diastolic diameter showed no remodeling and stable left ventricular dimensions after G-CSF stimulation, whereas left ventricular end-diastolic diameter in controls revealed enlargement from 55+/-4 mm at baseline to 58+/-4 mm (P<0.05 versus baseline) at 12 months after infarction and no improvement in diastolic function.
Mobilization of MNC(CD34+) by G-CSF after primary PCI may offer a pragmatic strategy for improvement in ventricular function and prevention of left ventricular remodeling 1 year after acute myocardial infarction.]]></description><subject>Adult</subject><subject>Angioplasty, Balloon, Coronary</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Cell Count</subject><subject>Blood vessels and receptors</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Coronary Angiography</subject><subject>Coronary heart disease</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Heart</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - complications</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - therapy</subject><subject>Postoperative Care</subject><subject>Prospective Studies</subject><subject>Stents</subject><subject>Treatment Outcome</subject><subject>Ventricular Function, Left</subject><subject>Ventricular Remodeling - drug effects</subject><subject>Vertebrates: cardiovascular system</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUk1v1DAQDQhEl8JfQOYAgkMWO9_htlp1aaSlRWV7jibOuDVy7GI7i8Kvx9ldqeKCuNiemTfz3ownit4yumSsYJ_Wzc36drvaNddXq8vVktFsmSdZlZRPowULrzjL0_pZtKCU1nGZJslZ9NK5H8Es0jJ_EZ2FInldFfXiSfHN4h61l0YTI4hC4clsW8lHBZZYHEyPSuo78kv6e3JnQY_K8Mkj4UYZPcXOyyFg_YwRwL2xBITHcPIxoIbJcLC9BEWkFmD5zPWZbKQOHhZPeGBxo_JuVuDvkQhrtI-l9hjoPPYhvgd3ECR_w0Er6J44jwPhqBRRskN7DEhNcG_UflbzDwGkm_6zlw-b5ub7bttcXcSrr81HEkYD6lX0XIBy-Pp0n0e3m4vd-jLeXn9p1qttzJM88TFUILIsw6JkwFOgiSg6GmZf9tB1iCJLoKbAa-gZVmlWZWme86ISjOUFhTxPz6P3x7oP1vwc0fl2kG5uGTSa0bVFlZc0T9IArI9Abo1zFkX7YOUAdmoZbeelaf9emuDO2uPShNw3J5KxG7B_zDxtSQC8OwHCL4ASYW5cukdcyWpa11n6B9OK1ks</recordid><startdate>20050830</startdate><enddate>20050830</enddate><creator>INCE, Hüseyin</creator><creator>PETZSCH, Michael</creator><creator>KLEINE, Hans Dieter</creator><creator>ECKARD, Heike</creator><creator>REHDERS, Tim</creator><creator>BURSKA, Detlev</creator><creator>KISCHE, Stephan</creator><creator>FREUND, Mathias</creator><creator>NIENABER, Christoph A</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050830</creationdate><title>Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial</title><author>INCE, Hüseyin ; PETZSCH, Michael ; KLEINE, Hans Dieter ; ECKARD, Heike ; REHDERS, Tim ; BURSKA, Detlev ; KISCHE, Stephan ; FREUND, Mathias ; NIENABER, Christoph A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c252t-a8af444e671ac3a02f6b06157dabbeef42a90ac9ad1e83484355c68f11560a553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Angioplasty, Balloon, Coronary</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Cell Count</topic><topic>Blood vessels and receptors</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Coronary Angiography</topic><topic>Coronary heart disease</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Heart</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - complications</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - therapy</topic><topic>Postoperative Care</topic><topic>Prospective Studies</topic><topic>Stents</topic><topic>Treatment Outcome</topic><topic>Ventricular Function, Left</topic><topic>Ventricular Remodeling - drug effects</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>INCE, Hüseyin</creatorcontrib><creatorcontrib>PETZSCH, Michael</creatorcontrib><creatorcontrib>KLEINE, Hans Dieter</creatorcontrib><creatorcontrib>ECKARD, Heike</creatorcontrib><creatorcontrib>REHDERS, Tim</creatorcontrib><creatorcontrib>BURSKA, Detlev</creatorcontrib><creatorcontrib>KISCHE, Stephan</creatorcontrib><creatorcontrib>FREUND, Mathias</creatorcontrib><creatorcontrib>NIENABER, Christoph A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>INCE, Hüseyin</au><au>PETZSCH, Michael</au><au>KLEINE, Hans Dieter</au><au>ECKARD, Heike</au><au>REHDERS, Tim</au><au>BURSKA, Detlev</au><au>KISCHE, Stephan</au><au>FREUND, Mathias</au><au>NIENABER, Christoph A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2005-08-30</date><risdate>2005</risdate><volume>112</volume><issue>9</issue><spage>I73</spage><epage>I80</epage><pages>I73-I80</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract><![CDATA[Experimental and clinical evidence has recently shown that pluripotent stem cells can be mobilized by granulocyte colony-stimulating factor (G-CSF) and may enhance myocardial regeneration early after primary percutaneous coronary intervention (PCI) management of acute myocardial infarction. Sustained or long-term effects of mobilized CD34-positive mononuclear stem cells, however, are unknown.
Thirty consecutive patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab were selected for the study 85+/-30 minutes after PCI; 15 patients were randomly assigned to receive subcutaneous G-CSF at 10 microg/kg body weight for 6 days in addition to standard care including aspirin, clopidogrel, an angiotensin-converting enzyme inhibitor, beta-blocking agents, and statins. In patients with comparable demographics and clinical and infarct-related characteristics, G-CSF stimulation led to sustained mobilization of CD34 positive mononuclear cells (MNC(CD34+)), with a 20-fold increase (from 3+/-2 at baseline to 66+/-54 MNC(CD34+)/microL on day 6; P<0.001); there was no evidence of leukocytoclastic effects, accelerated restenosis rate, or any late adverse events. Within 4 months, G-CSF-induced MNC(CD34+) mobilization led to enhanced resting wall thickening in the infarct zone of 1.16+/-0.29 mm (P<0.05 versus control), which was sustained at 1.20+/-0.28 after 12 months (P<0.001 versus control). Similarly, left ventricular ejection fraction improved from 48+/-4% at baseline to 54+/-8% at 4 months (P<0.005 versus control) and 56+/-9% at 12 months (P<0.003 versus control and paralleled by sustained improvement of wall-motion score index from 1.70+/-0.22 to 1.42+/-0.26 and 1.33+/-0.21 at 4 and 12 months, respectively), after G-CSF (P<0.05 versus baseline and P<0.03 versus controls). Accordingly, left ventricular end-diastolic diameter showed no remodeling and stable left ventricular dimensions after G-CSF stimulation, whereas left ventricular end-diastolic diameter in controls revealed enlargement from 55+/-4 mm at baseline to 58+/-4 mm (P<0.05 versus baseline) at 12 months after infarction and no improvement in diastolic function.
Mobilization of MNC(CD34+) by G-CSF after primary PCI may offer a pragmatic strategy for improvement in ventricular function and prevention of left ventricular remodeling 1 year after acute myocardial infarction.]]></abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>16159869</pmid><doi>10.1161/CIRCULATIONAHA.104.524827</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2005-08, Vol.112 (9), p.I73-I80 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68570523 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Angioplasty, Balloon, Coronary Antibodies, Monoclonal - therapeutic use Anticoagulants - therapeutic use Biological and medical sciences Blood and lymphatic vessels Blood Cell Count Blood vessels and receptors Cardiology. Vascular system Cardiovascular Agents - therapeutic use Combined Modality Therapy Coronary Angiography Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Drug Therapy, Combination Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Granulocyte Colony-Stimulating Factor - therapeutic use Heart Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cells - drug effects Humans Immunoglobulin Fab Fragments - therapeutic use Male Medical sciences Middle Aged Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - therapy Postoperative Care Prospective Studies Stents Treatment Outcome Ventricular Function, Left Ventricular Remodeling - drug effects Vertebrates: cardiovascular system |
| title | Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A41%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20left%20ventricular%20remodeling%20with%20granulocyte%20colony-stimulating%20factor%20after%20acute%20myocardial%20infarction:%20Final%201-year%20results%20of%20the%20front-integrated%20revascularization%20and%20stem%20cell%20liberation%20in%20evolving%20acute%20myocardial%20infarction%20by%20granulocyte%20colony-stimulating%20factor%20(FIRSTLINE-AMI)%20trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=INCE,%20H%C3%BCseyin&rft.date=2005-08-30&rft.volume=112&rft.issue=9&rft.spage=I73&rft.epage=I80&rft.pages=I73-I80&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIRCULATIONAHA.104.524827&rft_dat=%3Cproquest_cross%3E68570523%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68570523&rft_id=info:pmid/16159869&rfr_iscdi=true |